Gilead Sciences has received a US Food and Drug Administration (FDA) approval for the label expansion of its human immunodeficiency virus -1 (HIV-1) fixed combination therapy, Biktarvy (bictegravir ...
– Perinatal Guidelines Recognize Biktarvy as Alternative Regimen for Use During Pregnancy and for Those Trying to Conceive – The updated label now includes additional data from Study 5310, a Phase 1b, ...
Gilead Sciences (NASDAQ:GILD) has reached settlement agreements with Lupin, Cipla, and Laurus Labs to resolve patent disputes related to Biktarvy, a medication for HIV. These companies had sought ...
To make Cabenuva the standard treatment option for HIV, Johnson & Johnson and GSK-owned ViiV Healthcare must first dethrone Gilead Sciences’ once-daily stalwart Biktarvy. Now, the partners have a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback